2015;25(Suppl.1):65[Abstract]. Clinical Study FAE-BIL-2012 02 in Module 5.3.5 Reports of Efficacy and Safety Studies: Post-authorization study to assess the safety profile of Bilastine 20 mg in patients 65 years old; 2014. Module 2.5. Clinical Overview. 2.5.5. Overview of Safety. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011; 10(5): 779 93.

Pittsburgh, PA: Oncology Nursing Society. Shah NP, Guilhot F, Cortes JE et al. Long-term outcome with dasatinib after imatinib failure in chronic- phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10;123(15):2317-24. Lilly MB, Ottmann OG, Shah NP et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar.

Surg Today. 2017 Jul; 47(7):844-850. Abo-Ryia M, Abd-Allah H, El-Khadrawy O, Moussa G, Predictors of Gallstone Formation in Morbidly Obese Patients after Bariatric Surgery: A Retrospective Observational Study, Surgical Science. 2014, (5)1:1-5. Adams LB, Chang C, Pope J, Kim Y, Liu P, Yates A. Randomized, Prospective Comparison of Ursodeoxycholic Acid for the Prevention of Gallstones after Sleeve Gastrectomy. Obes Surg. 2016 May; 26(5):990-4. Attilli A.F.

Referências Bibliográficas Clinical Study Report PIPF-016, A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. 22 May 2014. Clinical Study Report PIPF-004: A randomized, double-blind, placebo-controlled, phase 3, three-arm study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis. Report No. 1065293, June 2009.

2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Product Information Addition of new clinical data from Study D2344 (China), Study D1301 (Japan) and Study DUS44 extension sections Clinical and ADR. Novartis. 6-May-2014. Tekin S, Hsu C, Etropolski M, Clinical Study Report ENA713B2311, A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3 12 mg/day of Exelon (Rivastigmine) Capsules in Patients with Parkinson s Disease Dementia.

2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Product Information Addition of new clinical data from Study D2344 (China), Study D1301 (Japan) and Study DUS44 extension sections Clinical and ADR. Novartis. 6-May-2014. Tekin S, Hsu C, Etropolski M, Clinical Study Report ENA713B2311, A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3 12 mg/day of Exelon (Rivastigmine) Capsules in Patients with Parkinson s Disease Dementia.

2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Product Information Addition of new clinical data from Study D2344 (China), Study D1301 (Japan) and Study DUS44 extension sections Clinical and ADR. Novartis. 6-May-2014. Exelon/Prometax (rivastigmine). 2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Exelon Patch 15 in patients with Alzheimer s dementia. Novartis. 8-Nov-2011. Exelon/Prometax (rivastigmine). 2.5 Clinical Overview.

JAMA Neurol. 2017;74(2):216 224. Borgohain R, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motorfluctuations. Mov Disord. 2014; 29(2):229 37 CARACTERÍSTICAS FARMACOLÓGICAS Propriedades farmacodinâmicas Mecanismo de ação: A safinamida atua através de mecanismos de ação dopaminérgicos e não dopaminérgicos.

Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63 (2): 259-64. População pediátrica Não existem dados disponíveis com Triplixam em crianças. CARACTERÍSTICAS FARMACOLÓGICAS Grupo terapêutico inibidores da ECA, combinações. Inibidores da ECA, bloqueadores do canal de cálcio e diuréticos.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axilary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG);Breast Cancer Res Treat;2014; Volume 148: 591 597. B. Gerber, S. Loibl, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch, H. Eggemann7, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch, G. Kunz, J. U. Blohmer, J. Huober, M. Hauschild, V. Nekljudova, M.